Skip to main content
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. — Investor Relations & Filings

Ticker · PTHS ISIN · US1711261057 US Manufacturing
Open in API
Filings indexed 205 across all filing types
Latest filing 2023-10-25 Regulatory Filings
Country US United States of America
Listing US PTHS

About Pelthos Therapeutics Inc.

https://ir.pelthos.com/

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing innovative therapeutic products for patients with unmet medical needs. Its lead product is ZELSUVMI™ (berdazimer topical gel, 10.3%), the first FDA-approved, at-home prescription treatment for molluscum contagiosum. ZELSUVMI is based on the company's proprietary nitric oxide-releasing technology platform, NITRICIL™, which is also being utilized for a pipeline of other product candidates. The company's portfolio also includes the acquired asset Xepi (ozenoxacin) Cream, 1%.

Recent filings

Filing Released Lang Actions
S-1/A
Regulatory Filings Classification · 100% confidence The document is an Amendment No. 7 to Form S-1 Registration Statement filed with the SEC by Chromocell Therapeutics Corporation. It is a registration statement under the Securities Act of 1933 for an initial public offering (IPO) of common stock. The text includes detailed information about the offering, shares to be sold, underwriters, and related legal and financial disclosures typical of an S-1 filing. This is not an annual report, earnings release, or any other type of financial report but a registration statement for securities offering. According to the filing definitions, registration statements such as Form S-1 are best classified under Regulatory Filings (RNS) as they are general regulatory announcements and compliance documents that do not fit into other specific categories.
2023-10-25 English
Regulatory Filings 2023
Regulatory Filings
2023-10-24 English
FWP
Capital/Financing Update Classification · 95% confidence The document is titled as an "Issuer Free Writing Prospectus" (FWP) filed pursuant to Rule 433 of the Securities Act of 1933, relating to a preliminary prospectus and registration statement for a securities offering. It contains detailed information about the company's drug development pipeline, management team, use of proceeds, capitalization table, and clinical trial plans. The content focuses on providing potential investors with information about the offering and the company's business and development plans. This type of document is a marketing and disclosure document used in securities offerings, not a financial report, earnings release, or regulatory filing about financial results or governance. It is not an Annual Report, Interim Report, Earnings Release, or any other financial or governance report. It is also not a Proxy Statement or Voting Results announcement. The document is a Free Writing Prospectus, which is a type of offering document used in capital raising. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to the company's fundraising and capital raising activities through an IPO offering.
2023-10-16 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a correspondence letter from Chromocell Therapeutics Corporation to the SEC staff responding to comments on Amendment No. 5 to a Registration Statement on Form S-1. It discusses updates and clarifications related to clinical trial plans and disclosures in Amendment No. 6 to the Form S-1. The document is not a financial report, earnings release, or any form of annual or quarterly report. It is a regulatory correspondence related to a registration statement filing, which fits best under Regulatory Filings (RNS). The document length is 4180 characters, which is relatively short and consistent with a letter or regulatory correspondence rather than a full report.
2023-10-14 English
S-1/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A registration statement filed with the SEC, specifically an amendment to a registration statement for an initial public offering (IPO) by Chromocell Therapeutics Corporation. It contains detailed disclosures about the offering, including the number of shares, pricing, underwriters, and legal disclaimers. This type of filing is related to capital raising and financing activities, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual registration statement document. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a substantive filing, not a brief announcement or certification.
2023-10-14 English
Regulatory Filings 2023
Regulatory Filings
2023-09-12 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.